The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
Sign Up to like & getrecommendations! Published in 2021 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2021.1970744
Abstract: ABSTRACT Introduction A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose reducing effect… read more here.
Keywords: hypothetical molecular; glp1 ras; receptor agonists; molecular mechanism ... See more keywords
641-P: Novel Microsphere Formulation Developments of Long-Acting GLP-1 RA Including Exenatide, Liraglutide, and Semaglutide
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-641-p
Abstract: Objective: Clinical applications of Glucagon-like peptide-1 receptor agonists (GLP1-RA) were greatly limited due to its short half-life. The current study aims at the formulation and characterization of sustained-release (SR)-GLP1-RAs to prolong the release profile with… read more here.
Keywords: lag phase; long acting; liraglutide semaglutide; formulation ... See more keywords
Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2022 at "Australian journal of general practice"
DOI: 10.31128/ajgp-07-21-6057
Abstract: BACKGROUND Type 2 diabetes (T2D) is a national health priority. Its rising prevalence is accompanied by a high burden of diabetes-related complications, many of which are preventable. Numerous glucose-lowering medications have been developed in recent years with growing… read more here.
Keywords: glp1 ras; glp1; glucagon like; peptide receptor ... See more keywords